Bordetella pertussis immunogenic vaccine compositions
Inventors
Kapre, Subhash V. • Michon, Francis
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10751404-B2
Publication Date
2020-08-25
Expiration Date
Abstract
This invention is directed to composition, vaccines, tools and methods in the treatment and prevention of Bordetella pertussis. In particular, the invention is directed to a three-pronged approach that involves removal of the nonessential vaccine components, use of a nondenatured, genetically detoxified mutant, and adding virulence factors.
Core Innovation
The described approach concerns manufacturing an immunogenic composition comprising a detoxified pertussis toxin, a detoxified pertussis adenylate cyclase toxin, a Toll-like receptor agonist, and an immunogenic oligosaccharide or fragment derived from a Bordetella pertussis lipooligosaccharide. The oligosaccharide or fragment is conjugated to a carrier protein or peptide. The composition combines these components as a pertussis vaccine approach.
The background section is not included in the partial patent content, so the problem it identifies is not explicitly described in patent. The stated aims are to elicit toxin-neutralizing and bactericidal antibodies and Th1/Th17 immune responses, and to reduce nasopharyngeal colonization and carriage. The partial content also identifies a dodecasaccharide core, a pentasaccharide hapten, and a synthetic LOS trisaccharide epitope.
Claims Coverage
The provided claims identify one independent claim, directed to manufacturing an immunogenic composition. Its main claim elements are summarized in three inventive features.
Detoxified pertussis toxins
The method comprises detoxified pertussis toxin and detoxified pertussis adenylate cyclase toxin.
Carrier-conjugated immunogenic oligosaccharide
The immunogenic oligosaccharide or fragment is obtained or derived from a B. pertussis lipooligosaccharide and is conjugated to a carrier protein or peptide.
Composition with a Toll-like receptor agonist
The detoxified toxins, Toll-like receptor agonist, and immunogenic oligosaccharide or fragment are combined to form the immunogenic composition.
The independent claim covers a method of manufacturing an immunogenic composition with two detoxified pertussis toxins, a Toll-like receptor agonist, and a carrier-conjugated, lipooligosaccharide-derived immunogenic oligosaccharide or fragment.
Stated Advantages
The approach aims to elicit toxin-neutralizing and bactericidal antibodies and Th1/Th17 immune responses.
The approach aims to reduce nasopharyngeal colonization and carriage.
Documented Applications
A pertussis vaccine approach using an immunogenic composition intended to address B. pertussis infection, nasopharyngeal colonization, and carriage.
Interested in licensing this patent?